II
COLL icon

Ibex Investors’s Collegium Pharmaceutical COLL Stock Holding History

Ibex Investors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-11,421
Closed -$292K – 175
2018
Q1 		$292K Buy
+11,421
New +$272K 0.24% 146

Other funds holding COLL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Ibex Investors's COLL Position: Q2 2018 in Review

Ibex Investors sold out of Collegium Pharmaceutical (COLL) in Q2 2018, closing a stake of 11,421 shares — an estimated $292K sold.

Ibex Investors first reported a position in COLL in Q1 2018 and held it in 1 quarter. The position peaked at $292K in Q1 2018. 133 funds tracked by Wall St. Rank hold COLL as of Q2 2018.

  • Ibex Investors reported no remaining Collegium Pharmaceutical position as of Q2 2018 after selling out during the quarter.
  • Ibex Investors sold 11,421 Collegium Pharmaceutical shares in Q2 2018, an estimated $292K.
  • Ibex Investors first reported a position in Collegium Pharmaceutical in Q1 2018 and held it in 1 quarter.
  • Ibex Investors's Collegium Pharmaceutical position peaked at $292K in Q1 2018.
  • 133 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2018.

Based on Ibex Investors's 13F filing for Q2 2018, filed 14 Aug 2018.